Physician profile
Carter D Paddock
NPI 1467541797
$4,049.17
in general payments reported to CMS, 2019-2025
15 companies · $1,063 in 2025
The $1,063 reported for 2025 was more than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114 · 2020: $189 · 2021: $341 · 2022: $480 · 2023: $994 · 2024: $869 · 2025: $1,063.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,660 · Education: $265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,660.11 |
| Education | $265.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,389.89 | 2019-2025 | |
| Janssen Biotech, INC. | $653.80 | 2023-2025 | Tremfya |
| Abbvie INC. | $622.80 | 2023-2025 | |
| Galderma Laboratories, L.P. | $517.25 | 2021-2025 | Dysport |
| Allergan, INC. | $198.55 | 2019-2022 | |
| Biofrontera INC. | $165.31 | 2022-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Sun Pharmaceutical Industries INC. | $125.68 | 2020-2022 | |
| Pfizer INC. | $124.97 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $83.79 | 2019-2025 | Dupixent |
| Ucb, INC. | $80.17 | 2019-2025 | Bimzelx |
| Verrica Pharmaceuticals INC. | $28.06 | 2023 | Ycanth |
| Lilly USA, LLC | $21.73 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $17.90 | 2024 | Sotyktu |
| Leo Pharma INC. | $15.37 | 2023 | Adbry |
| Organon LLC | $3.90 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carter Paddock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.